The past suppression of industry knowledge of the toxicity of benzene to humans and potential bias in future benzene research

International Journal of Occupational and Environmental Health

Volumn 12, Issue 3, 2006, Pages 268-272

  Infante, Peter F ^a  

^a NONE   (United States)

Author keywords

Benzene; Bias; Blood disease; Industry ethics; Leukemia; Petrochemicals

Indexed keywords

BENZENE;

CHINA; ENVIRONMENTAL EXPOSURE; FINANCE; HUMAN; PETROCHEMICAL INDUSTRY; PRIORITY JOURNAL; RESEARCH; REVIEW; UNITED STATES;

EID: 33747883867     PISSN: 10773525     EISSN: None     Source Type: Journal    
DOI: 10.1179/oeh.2006.12.3.268     Document Type: Review

References (47)

1. Gennaro V, Tomatis L. Business bias: how epidemiological studies may underestimate or fail to detect increased risks of cancer and other diseases. Int J Occup Environ Health. 2005;11;356-9.
2. Michaels D, Monforton C, Lurie P. Selected science: an industry campaign to undermine an OSHA hexavalent chromium standard. Environ Health: A Global Access Scientific Source, 2006;5:5.
3. Occupational Safety and Health Administration. Occupational Exposure to Hexavalent Chromium; Final Rule, February 28, Part II. Fed Reg. 2006;71:10099-385.
4. Barrow CS, Conrad JWJr. Assessing the reliability and credibility of industry science and scientists. Environ Health Perspect. 2006;114:153-5.
5. Occupational Safety and Health Administration. Occupational Exposure to Benzene: Emergency Temporary Standards-Hearing, May 3, Part IV. Fed Reg. 1977;42:22516-22529.
6. Picciano D. Cytogenic study of workers exposed to benzene. Environ Res. 1979;19:33-8.
7. Daniel RL. Cytogenic study of workers exposed to benzene in the Texas Division of Dow Chemical U.S.A.; industrial hygiene data base. 1980. Unpublished manuscript submitted to OSHA by Venable JR, Director, U.S. Area Medical in response to request from OSHA staff.
8. Infante PF, White MC. Benzene: epidemiologic observations of leukemia by cell type and adverse health effects associated with low-level exposure. Environ Health Perspect. 1983;52:75-82.
9. Occupational Safety and Health Administration. Occupational Exposure to Benzene: Fed Reg. 1978;43:5918-80.
10. Infante PF, Biometry Section, IWSB, NIOSH, October 31, 1977. Letter inquiring about the status of the cytogenetic study results, to HC Scharnweber, Corporate Medical Director, Dow Chemical Company.
11. Infante PF, Biometry Section, IWSB, NIOSH, January 4, 1978. Letter requesting cytogenetic study results or raw data, to D Picciano, Dow Chemical USA.
12. Infante PF, Biometry Section, IWSB, NIOSH, January 17, 1978. Letter requesting cytogenetic study results, to E Blair, Director, Health and Environmental Research, Dow Chemical USA.
13. Scharnweber HC, Corporate Medical Director, November 22, 1977. Letter stating the Dow cytogenetic study was still in progress due to incomplete benzene exposure determination, to PF Infante, Division of Surveillance, Hazard Evaluation and Field Studies, NIOSH.
14. Picciano D, Occupational Health and Medical Research, Dow Chemical Company, January 10, 1978. Letter stating that cytogenetic study results must be cleared by E Blair of Dow Chemical, to PF Infante, Division of Surveillance, Hazard Evaluation and Field Studies, NIOSH.
15. Holder BB, Director, Biomedical Research, Dow Chemical Company, March 1, 1978. Letter transmitting results of two cytogenetic studies, to PF Infante, Biometry Section, DSHEFS, NIOSH.
16. Picciano D, Occupational Health and Medical Research, Dow Chemical Company, October 7, 1977. Internal memorandum recommending worker notification of cytogenetic study results and recommendations for medical and industrial hygiene measures to be taken, sent to BB Holder, Director, Biomedical research, Dow Chemical Company.
17. Business Week. Research that clouds the benzene issue. June 26, 1978: 42-3.
18. Occupational Safety and Health Administration. Occupational exposure to benzene: request for information, regulatory schedule. Fed Reg. 1983;48:31412-4.
19. Occupational Safety and Health Administration. Occupational exposure to benzene; proposed rule and notice of hearing, Fed Reg. 1985;50:50512-86.
20. Irons RD, Toxicologist, Chemical Industry Institute of Toxicology, May 23, 1984. Letter discussing progress of CUT benzene cytogenetic study, to P Infante, Director, Office of Standards Review, OSHA.
21. Infante PF, Director, Office of Standards Review, OSHA, November 9, 1984. Letter requesting cytogenetic study results, to AD Kligerman, Chemical Industry Institute of Toxicology.
22. Neal RA, President, Chemical Industry Institute of Toxicology, November 14, 1984. Letter stating that slides for the rat portion of cytogenetic study are currently being reviewed, to PF Infante, Director, Office of Standards review, OSHA.
23. Vance RL, Director, Health Standards Program, OSHA, Feb 5, 1985. Letter stating that OSHA has been informed by EPA that the CUT benzene cytogenetic study demonstrates dose-related effects at 1 ppm and requesting the results from CIIT, to RA Neal, President, Chemical Industry Institute of Toxicology.
24. Neal RA, President, Chemical Industry Institute of Toxicology, February 13, 1985. Letter stating the reading of the slides related to cytogenetic findings in rats have just been completed, to RL Vance, Director, Health Standards Program, OSHA.
25. Neal RA, Director, Chemical Industry Institute of Toxicology, June 7, 1985. Letter transmitting CUT cytogenetic study results, to RL Vance, Director, Health Standards Programs, OSHA.
26. Durham Morning Herald. Park lab denies delaying results of benzene tests. June 6, 1985.
27. Kover FD, Chief, Chemical Screening Branch, EPA, February 6, 1985. Letter stating EPA has been informed of adverse cytogenetic effects in rats exposed to 1 ppm benzene and higher in the CUT study, to PF Infante, Director, Office of Standards Review, OSHA.
28. Kusnetz HL, Manager, Safety and Industrial Hygiene, Shell Oil Company, July 28, 1983. Letter transmitting initial mortality study results of Wood River and Deer Park facilities, to T Auchter, Director, OSHA.
29. Austin WB, Phillips CF. Development and implementation of a health surveillance system. Am Indust Hyg Assoc J. 1983;44:638-42.
30. Infante PF, Director, Office of Standards Review, OSHA, January 27, 1984. Letter requesting data for blood abnormalities among benzene exposed workers, to Howard L. Kusnetz, Manager, Safety and Industrial Hygiene, Shell Oil Company.
31. Infante PF, Director, Office of Standards Review, OSHA, February 22, 1984. Letter requesting data for blood abnormalities among benzene-exposed workers, to RE Joyner, Director, Corporate Medical Department, Shell Oil Company.
32. Joyner RE, Director, Corporate Medical Department, Shell Oil Company, February 13, 1984. Letter stating no employee meeting benzene exposure criteria had a blood abnormality, to PF Infante, Director, Office of Standards Review, OSHA.
33. Joyner RE, Director, Corporate Medical Department, Shell Oil Company, March 5, 1984. Letter asking OSHA to redefine its criteria in requesting data related to blood abnormalities, to PF Infante, Director, Office of Standards Review, OSHA.
34. Kusnetz HL, Manager, Safety and Industrial Hygiene, Shell Oil Company, March 5, 1984. Letter asking OSHA Director to alleviate Shell Oil Company from benzene data requests by Dr. Infante, to T Auchter, Director, OSHA.
35. Infante PF, Director, Office of Standards Review, OSHA. April 17, 1984. Letter requesting data for blood abnormalities among benzene-exposed workers, to RE Joyner and HL Kusnetz, Corporate Medical Department, Shell Oil Company.
36. Joyner RE, Kusnetz HL, Corporate Medical Director and Manager, Safety and Industrial Hygiene, Shell Oil Company, May 17, 1984. Letter providing data for Shell benzene-exposed workers with blood abnormalities, to PF Infante, Director, Office of Standards Review, OSHA.
37. Kusnetz HL. President's Page; August Potpourri. Am Indust Hyg Assoc J. 1985;46:A-4.
38. Rinsky RA, Smith AB, Hornung R, et al. Benzene and leukemia: an epidemiologic risk assessment. N Engl J Med. 1987;316:1044-50.
39. Occupational Safety and Health Administration. Occupational Exposure to Benzene: Final Rule, September 11, Part II. Fed Reg. 1987;52:34460-578.
40. Hayes RB, Ym SN, Dosemeci M, Li GL, Wacholder S, Travis LB, et al. Benzene and the dose-related incidence of hematologic neoplasms in China. Chinese Academy of Preventive Medicine-National Cancer Institute Benzene Study Group. J Natl Cancer Inst. 1997;89,1065-71.
41. Lan Q, Zhang L, Li G, et al. Hematotoxicity in workers exposed to low levels of benzene. Science. 2004;306:1774-6.
42. Qu Q, Shore R, Li G, et al. Hematological changes among Chinese workers with a broad range of benzene exposures. Am J Ind Med. 2002;42:275-85.
43. Wong O. A critique of the exposure assessment in the epidemiologic study of benzene-exposed workers in China conducted by the Chinese Academy of Preventive Medicine and the US National Cancer Institute. Regul Toxicol Pharmacol. 1999;30: 259-67.
44. Budinsky RA, DeMott RP, Wernke MJ, Schell JD. An evaluation of modeled benzene exposure and dose estimates published in the Chinese-National Cancer Institute collaborative epidemiology studies. Regul Toxicol Pharmacol. 1999;30:244-58.
45. Hayes RB, Songnian Y, Dosemeci M, Linet M. Benzene and lymphohematopoietic malignancies in humans. Am J Ind Med. 2001;40:117-26.
46. Cappiello D. Oil industry funding study to contradict cancer claims. Houston Chronicle. April 29, 2005.
47. Mehlman MA, Adjunct Professor, Robert Wood Johnson School of Medicine, June 29 and 30, 2005. Letter requesting the companies that are funding the API benzene research in Shanghai to transfer the research to an independent body, to D O'Reilly, Chairman of the Board and CEO, Chevron Texaco Corp, J Hofmeister, President, Shell Oil Co, US, LE Raymond, Chairman and CEO, Exxon Mobil Chemical Co., and President and CEO, British Petroleum Co., UK.